Antimetastatic action of diltiazem on LS/BL tumor cells in liver tumor-colony assay.
Inhibition of experimental metastases of lymphosarcoma LS/BL cells by diltiazem, a calcium blocking agent, was tested. Diltiazem treatment (2 X 30 mg/kg p.o. for 12 days) resulted in a maximum of 72.8% inhibition of liver metastases. The authors suggest that diltiazem might become suitable candidate for antimetastatic treatment in humans.
Jurásková
V
V
Institute of Biophysics, Czechoslovak Academy of Sciences, Brno.
Sládek
T
T
D000818:Animals; D000970:Antineoplastic Agents; D002460:Cell Line; D004110:Diltiazem / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D005260:Female; D007928:Lethal Dose 50; D008113:Liver Neoplasms / Q000517:prevention & control / Q000556:secondary*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009362:Neoplasm Metastasis; D009360:Neoplastic Cells, Circulating / Q000187:drug effects*
D000970:Antineoplastic Agents; D004110:Diltiazem